Ttie objective of ttiis proposed study is to investigate ttie degree to wtiichi nnetfornnin, a lifestyle intervention, or both, can reduce breast cancer mortality among overweiqtit/obese, postmenopausal breast cancer survivors. We will use a "Biomarker Bridge" design that links clinical outcomes from a breast cancer survivor cohort with intermediate outcomes from a randomized controlled trial by means of a Biomarker Risk Score. Biomarker Risk Score Development: We will assay panels of interrelated biomarkers in 375 archived blood samples obtained from oven/veight/obese, postmenopausal women with a history of breast cancer (125 cases [breast cancer death]:250 matched controls). These Biomarkers represent proposed mechanisms by which obesity is associated with postmenopausal breast cancer: (1) alterations in the insulin-IGF axis, (2) concentrations of endogenous sex hormones, and (3) chronic inflammation. We will identify a set of markers that best predicts breast cancer mortality using conditional logistic regression models adjusted for prognostic factors. This model (i.e., Biomarker Risk Score) measures the log-odds of disease risk due to joint biomarker concentrations. Therefore this Risk Score can measure changes in log-odds due to changes in these markers in an individual and will be used to assess the clinical impact of the metformin and lifestyle intervention randomized trial. Metformin/Lifestyle Intervention Trial: We will conduct a 6-month, randomized controlled trial in 340 overweight/obese, postmenopausal breast cancer survivors. Participants will be randomized in equal numbers to (1) placebo, (2) metformin, (3) lifestyle intervention and placebo, or (4) lifestyle intervention and metformin. The lifestyle intervention will focus on reducing energy intake and increasing energy expenditure to achieve a 7% weight reduction. Biomarkers that compose the Risk Score will be assayed in fasting blood samples collected at baseline and 6 months. The degree to which each intervention changes (e.g., reduces) the Biomarker Risk Score will be used to predict changes (e.g., reductions) in breast cancer mortality. We hypothesize that metformin and lifestyle interventions will reduce breast cancer mortality and that the combination of those interventions will have an additive effect on lowering nsk. In summary, this Biomarker Bridge Design will (i) develop a Biomarker Risk Score that predicts breast cancer mortality, (ii) examine how a metformin/lifestyle intervention changes this Risk Score, and (iii) thereby assess the degree to which metformin and lifestyle interventions influence the biological processes linking obesity with breast cancer mortality.

Public Health Relevance

Given the high prevalence of obesity, research on interventions to reduce breast cancer risk in overweight and obese women is of considerable public health importance. A promising drug intervention to improve breast cancer prognosis is metformin, a drug used to treat diabetes. This proposed study will address whether a diet and physical activity lifestyle intervention that results in weight loss could be a viable alternative, or valuable addition, to a metformin intervention in breast cancer survivors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA155435-04
Application #
8688938
Study Section
Special Emphasis Panel (ZCA1-SRLB-4)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
4
Fiscal Year
2014
Total Cost
$253,552
Indirect Cost
$64,574
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Kerr, Jacqueline; Patterson, Ruth E; Ellis, Katherine et al. (2016) Objective Assessment of Physical Activity: Classifiers for Public Health. Med Sci Sports Exerc 48:951-7
Le, Tran; Flatt, Shirley W; Natarajan, Loki et al. (2016) Effects of Diet Composition and Insulin Resistance Status on Plasma Lipid Levels in a Weight Loss Intervention in Women. J Am Heart Assoc 5:
James, Peter; Jankowska, Marta; Marx, Christine et al. (2016) "Spatial Energetics": Integrating Data From GPS, Accelerometry, and GIS to Address Obesity and Inactivity. Am J Prev Med 51:792-800
Fernandez, Marina O; Sharma, Shweta; Kim, Sun et al. (2016) Obese neuronal PPARγ knock-out mice are leptin sensitive but show impaired glucose tolerance and fertility. Endocrinology :en20161818
Marinac, Catherine R; Nelson, Sandahl H; Breen, Caitlin I et al. (2016) Prolonged Nightly Fasting and Breast Cancer Prognosis. JAMA Oncol 2:1049-55
Schmitz, Kathryn H; Gehlert, Sarah; Patterson, Ruth E et al. (2016) TREC to WHERE? Transdisciplinary Research on Energetics and Cancer. Clin Cancer Res 22:1565-71
Chung, Heekyung; Chou, Winjet; Sears, Dorothy D et al. (2016) Time-restricted feeding improves insulin resistance and hepatic steatosis in a mouse model of postmenopausal obesity. Metabolism 65:1743-1754
Patterson, Ruth E; Marinac, Catherine R; Natarajan, Loki et al. (2016) Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors. Contemp Clin Trials 47:64-71
Mitchell, Jonathan A; Godbole, Suneeta; Moran, Kevin et al. (2016) No Evidence of Reciprocal Associations between Daily Sleep and Physical Activity. Med Sci Sports Exerc 48:1950-6
Cho, Chang Gun; Pak, Kwang; Webster, Nicholas et al. (2016) Both canonical and non-canonical NF-κB activation contribute to the proliferative response of the middle ear mucosa during bacterial infection. Innate Immun :

Showing the most recent 10 out of 31 publications